home · filing · 0001110803-23-000061
8-K filed August 9, 2023, 7:59 PM ET
ticker ILMN
CIK 0001110803
leadership
confidence high
sentiment neutral
materiality 0.55
Illumina CMO Phil Febbo departs Aug 7; CTO Alex Aravanis departs Aug 9, replaced by Steven Barnard
ILLUMINA, INC.
Dr. Phil Febbo, Chief Medical Officer, departed Illumina on August 7, 2023.
Dr. Alex Aravanis, Chief Technology Officer, departing August 9 to pursue another opportunity.
Dr. Steven Barnard appointed CTO effective immediately; Barnard joined Illumina in 1998 as first scientist.
Barnard previously VP of Global Advanced Science, holds >100 patents, led NovaSeq X series development.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Departed
Alex Aravanis
Chief Technology Officer
Effective 2023-08-09
Successor Steve Barnard
Filed August 9, 2023, 7:59 PM ET
on August 9, 2023, the Company announced that Dr. Alex Aravanis, who has served as Chief Technology Officer, will also depart the Company.
Appointed
Steve Barnard
Chief Technology Officer
Effective 2023-08-09
Filed August 9, 2023, 7:59 PM ET
the appointment of Dr. Steve Barnard as the Company’s new Chief Technology Officer, effective immediately
Departed
Phil Febbo
Chief Medical Officer
Effective 2023-08-07
Filed August 9, 2023, 7:59 PM ET
On August 7, 2023, Dr. Phil Febbo, Chief Medical Officer, departed Illumina, Inc. (the “Company”),
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Alex Aravanis departed as Chief Technology Officer at ILLUMINA, INC..
Action will depart
Role Chief Technology Officer
Exact text from the filing
on August 9, 2023, the Company announced that Dr. Alex Aravanis, who has served as Chief Technology Officer, will also depart the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steve Barnard was appointed as Chief Technology Officer at ILLUMINA, INC..
Action appointed
Role Chief Technology Officer
Exact text from the filing
the appointment of Dr. Steve Barnard as the Company’s new Chief Technology Officer, effective immediately
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Phil Febbo departed as Chief Medical Officer at ILLUMINA, INC..
Action departed
Role Chief Medical Officer
Exact text from the filing
On August 7, 2023, Dr. Phil Febbo, Chief Medical Officer, departed Illumina, Inc. (the “Company”),
View on SEC.gov
Source: SEC EDGAR
accession 0001110803-23-000061
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.